WO2026064441 - METHODS OF TREATING ALZHEIMER'S DISEASE
National phase entry is expected:
Publication Number
WO/2026/064441
Publication Date
26.03.2026
International Application No.
PCT/US2025/046857
International Filing Date
17.09.2025
Title **
[English]
METHODS OF TREATING ALZHEIMER'S DISEASE
[French]
MÉTHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER
Applicants **
OTHAIR PROTHENA LIMITED
ALBRECHT, Jiri
QUADRINI, Karen, J.
VERNHES, Frederique
Inventors
ALBRECHT, Jiri
QUADRINI, Karen, J.
VERNHES, Frederique
Priority Data
63/695,814
17.09.2024
US
63/745,549
15.01.2025
US
63/779,266
27.03.2025
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3643 | |
| EPO | Filing, Examination, Granting | 37917 | |
| Japan | Filing, Examination, Granting | 3418 | |
| South Korea | Filing, Examination, Granting | 4912 | |
| USA | Filing, Examination, Granting | 16310 |
Total:
66,200
Contact Us
Abstract[English]
The disclosure is related to methods of treating a subject with Alzheimer's Disease (AD) using anti-amyloid beta (Aβ) therapy. The patient may be treated based on the measurement and analysis of biomarker levels, such as plasma Aβ42/40 ratio, pTau181 and pTau217. The disclosure includes a systematic approach called CP Convert for converting biomarker measurements across different analytical platforms, enabling comparison of pTau217 data from LC-MS/MS, SIMOA, and chemiluminescent enzyme immunoassay platforms. Methods demonstrate that pTau217 has superior diagnostic accuracy compared to Aβ42/40 ratio and pTau181 for detecting brain amyloid positivity. Implementation of pTau217 prescreening can significantly reduce Aβ-PET testing, decreasing patient burden and clinical trial costs. The CP Convert methodology can be validated using independent cohorts, demonstrating robust cross-platform conversion for research applications.[French]
La divulgation concerne des méthodes de traitement d'un sujet atteint de la maladie d'Alzheimer (AD) à l'aide d'une thérapie anti-amyloïde bêta (AP). Le patient peut être traité sur la base de la mesure et de l'analyse de niveaux de biomarqueurs, tels que le rapport A042/4O du plasma, pTaulSl et pTau217. La divulgation comprend une approche systématique appelée conversion CP pour convertir des mesures des biomarqueurs entre différentes plateformes analytiques, ce qui permet la comparaison de données pTau217 provenant de LC-MS/MS, SIMOA et de plateformes d'immunoessais enzymatiques chimioluminescents. Les méthodes démontrent que pTau217 présente une précision de diagnostic supérieure à celle du rapport AP42/40 et pTaulSl pour détecter la positivité amyloïde cérébrale. La mise en œuvre du prédépistage de pTau217 peut réduire de manière significative les tests AP-PET, diminuant ainsi la charge pour le patient et les coûts des essais cliniques. La méthodologie de conversion CP peut être validée à l'aide de cohortes indépendantes, démontrant une conversion inter-plateforme robuste pour des applications de recherche.